Efficacy of adjuvant therapy regimens administered during the perioperative period in resectable non-small cell lung cancer
Adjuvant IT or ChIT potentialy benefit patients with resectable NSCLC receiving NCIT, particularly those without pCR and with positive PD-L1 expression.
Authors
- Kaiyue Wang (ORCID: https://orcid.org/0000-0001-6632-0654)
- Li Min (ORCID: https://orcid.org/0000-0001-8704-8805)
- Xue Meng (ORCID: https://orcid.org/0000-0001-7925-7295)
- Jing Xu (ORCID: https://orcid.org/0000-0002-9276-5128)
- Jiarui Zhao (ORCID: https://orcid.org/0000-0003-1240-3811)
- Jingyu Zhu (ORCID: https://orcid.org/0000-0002-1693-7370)
- Xingpeng Wang (ORCID: https://orcid.org/0009-0007-3674-6014)
- Xiaohan Wang (ORCID: https://orcid.org/0009-0009-9792-7972)
- Guoxin Cai
- Baiyang Huang
Institutions
- Weifang Medical University (CN)
- Shandong University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1007/s00262-025-04159-0
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Chinese Society of Clinical Oncology
- Youth Innovation Team Project for Talent Introduction and Cultivation in Universities of Shandong Province